Skip to content

Trial · Interventional

CompletedNot applicableRegistry data

The Interaction Between Appetite Hormones

NCTNCT02094183 (opens ClinicalTrials.gov in a new tab)Other idH-4-2010-134
Open at ClinicalTrials.govAsk about this trial

This trial does not test a peptide that PepBank tracks.

  • Names Glucagon, does not test it. It appears in the summary.

Overview

Status
Completed
Phase
Not applicable
Enrollment
58 participants (actual)
Sponsor
University of Copenhagen · Other
Design
Randomized · Single masking
Countries
1 country

Denmark

Start
Sept 2011
Primary completion
Apr 2014
Completion
Apr 2014
First posted
21 Mar 2014 (estimated)
Last update posted
8 Jul 2014 (estimated)
Conditions
Obesity

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20112012201320142015
  1. N/A

    The Interaction Between Appetite Hormones

    NCT02094183

    Sept 2011 to Apr 2014

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Glucagon Like Peptide (GLP) -1 affects metabolic response corrected for weight change

Interventions

  • GLP-1Other
  • low calorie dietDietary supplement

Arms2

  • Experimental

    GLP-1

    GLP-1 and low calorie diet

  • Experimental

    Control

    low calorie diet

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change in hormone level corrected for weight change

    Time frame · Baseline and week 52

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2015

6 results

GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.

Iepsen et al. 2015The Journal of clinical endocrinology and metabolismcited by 153

PMID 26043228DOI 10.1210/jc.2015-1176PUB-26043228

Rights unknown6 results
Source linkSee results (6)

More studies

1 study on this page

Indexing hint: In vitro study · 2021

Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease.

Akawi et al. 2021Journal of the American College of Cardiologycited by 93

PMID 34016263PMC8141611DOI 10.1016/j.jacc.2021.03.314PUB-34016263

CC BY
Download PDF

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

  • DerivedBrethvad AO, Zakariassen HL, Holt J, Lundgren JR, Jakobsen A, Hartmann B, Lehmann EW, Kissow H, Holst JJ, Madsbad S, Torekov SS, Holst B. Increased meal-induced neurotensin response predicts successful maintenance of weight loss - Data from a randomized controlled trial. Metabolism. 2023 Jun;143:155534. doi: 10.1016/j.metabol.2023.155534. Epub 2023 Mar 16. PMID 36933790

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 64 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * BMI \> 30 and \< 40 (kg/m2) * Healthy Exclusion Criteria: * Other known illness * Medicine that affects glucose- and lipid metabolism, appetite or food intake * Pregnancy * Breast feeding

PepBank is a research reference. Talk to a doctor before you use any peptide.